Catalyst Pharmaceuticals, Inc. (CPRX) Stock Analysis
Healthcare · Biotechnology
Wait for pullback to $29.59. Weak momentum — blocks BUY_NOW at $31.21. Engine's entry $29.59 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: AGAMREE and FYCOMPA licensing partners; Analyst target reached - limited upside remaining.
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company selling three FDA-approved rare-disease drugs: FIRDAPSE (LEMS), AGAMREE (DMD), and FYCOMPA (epilepsy). Revenue is derived from net U.S. product sales; the company held $709.2M in cash as of December 31,... Read more
Wait for pullback to $29.59. Weak momentum — blocks BUY_NOW at $31.21. Engine's entry $29.59 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: AGAMREE and FYCOMPA licensing partners; Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Wide-moat business. Accumulate on weakness. Score 5.9/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — Catalyst Pharmaceuticals, Inc.
Latest news
- Does Catalyst (CPRX) Have the Potential to Rally 28.87% as Wall Street Analysts Expect? - Yahoo Finance — Yahoo Finance positive
- See How Institutions Boost Catalyst Shares - FXEmpire — FXEmpire positive
- Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In Focus - Sahm — Sahm positive
- Catalyst Pharmaceuticals (CPRX) Q1 EPS Beat Reinforces High Margin Bull Narratives - simplywall.st — simplywall.st positive
- Catalyst Pharmaceuticals: Angelini Deal Caps A Potentially Better Story (NASDAQ:CPRX) - Seeking Alpha — Seeking Alpha positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierAGAMREE and FYCOMPA licensing partners10-K Item 1A: 'We are dependent on our licensing partner for supplies of AGAMREE® and FYCOMPA®'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $29.59. Weak momentum — blocks BUY_NOW at $31.21. Engine's entry $29.59 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Supplier: AGAMREE and FYCOMPA licensing partners; Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Wide-moat business. Accumulate on weakness. Target $31.91 (+2.2%), stop $28.73 (−8.6%), Setup A.R:R 2.6:1. Score 5.9/10, moderate confidence.
Take-profit target: $31.91 (+7.6% upside). Target $31.91 (+2.2%), stop $28.73 (−8.6%), Setup A.R:R 2.6:1. Stop-loss: $28.73.
Concentration risk — Supplier: AGAMREE and FYCOMPA licensing partners; Analyst target reached - limited upside remaining; Near 52-week high (4.1% away).
Catalyst Pharmaceuticals, Inc. trades at a P/E of 18.0 (forward 10.0). TrendMatrix value score: 6.7/10. Verdict: Buy (Wait for Entry).
14 analysts cover CPRX with a consensus score of 4.4/5. Average price target: $33.
What does Catalyst Pharmaceuticals, Inc. do?Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company selling three FDA-approved rare-disease drugs:...
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company selling three FDA-approved rare-disease drugs: FIRDAPSE (LEMS), AGAMREE (DMD), and FYCOMPA (epilepsy). Revenue is derived from net U.S. product sales; the company held $709.2M in cash as of December 31, 2025. Orphan drug exclusivity and specialty pharmacy distribution provide near-term revenue protection.